ATE332144T1 - Behandlung von herzhypertrophie - Google Patents

Behandlung von herzhypertrophie

Info

Publication number
ATE332144T1
ATE332144T1 AT99912711T AT99912711T ATE332144T1 AT E332144 T1 ATE332144 T1 AT E332144T1 AT 99912711 T AT99912711 T AT 99912711T AT 99912711 T AT99912711 T AT 99912711T AT E332144 T1 ATE332144 T1 AT E332144T1
Authority
AT
Austria
Prior art keywords
treatment
cardiac hypertrophy
hypertrophy
cardiac
Prior art date
Application number
AT99912711T
Other languages
English (en)
Inventor
Hongkui Jin
Hsienwie Lu
Nicholas J Paoni
Renhui Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE332144T1 publication Critical patent/ATE332144T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT99912711T 1998-04-02 1999-03-19 Behandlung von herzhypertrophie ATE332144T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8044898P 1998-04-02 1998-04-02

Publications (1)

Publication Number Publication Date
ATE332144T1 true ATE332144T1 (de) 2006-07-15

Family

ID=22157456

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06013719T ATE410181T1 (de) 1998-04-02 1999-03-19 Verwendung von intereferon gamma zur behandlung von herzhypertrophie
AT99912711T ATE332144T1 (de) 1998-04-02 1999-03-19 Behandlung von herzhypertrophie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06013719T ATE410181T1 (de) 1998-04-02 1999-03-19 Verwendung von intereferon gamma zur behandlung von herzhypertrophie

Country Status (17)

Country Link
US (2) US6187304B1 (de)
EP (2) EP1067958B1 (de)
JP (2) JP5030329B2 (de)
CN (1) CN1201814C (de)
AR (1) AR018174A1 (de)
AT (2) ATE410181T1 (de)
AU (1) AU757910B2 (de)
BR (1) BR9909422A (de)
CA (1) CA2325442C (de)
DE (2) DE69932235T2 (de)
DK (2) DK1702623T3 (de)
ES (2) ES2314786T3 (de)
IL (1) IL138812A0 (de)
NZ (1) NZ506854A (de)
TW (1) TWI243682B (de)
WO (1) WO1999051260A2 (de)
ZA (1) ZA200004854B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
NZ506854A (en) * 1998-04-02 2003-07-25 Genentech Inc Treatment of cardiac hypertrophy
CA2378179A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US7838225B2 (en) * 1999-10-29 2010-11-23 Hologic, Inc. Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
WO2002089828A2 (en) * 2001-05-04 2002-11-14 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
US20050079156A1 (en) * 2001-11-06 2005-04-14 Grace Wong Method of treating endometreosis
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
TWI337881B (en) * 2002-08-29 2011-03-01 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
US7972612B2 (en) * 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
EP2294183B1 (de) * 2008-06-18 2015-12-16 The Texas A&M University System Mesenchymale stammzellen, zusammensetzungen und verfahren zur behandlung von herzgewebeschäden
USD647411S1 (en) 2011-01-12 2011-10-25 Rain Bird Corporation Water timer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US4929544A (en) 1982-04-23 1990-05-29 Sri International Reagents, methods, and test kit for diagnosing/monitoring cancer in humans
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4944941A (en) 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US5151265A (en) 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
CA2069870E (en) 1989-12-01 2005-01-11 Donald Y. M. Leung Treatment of atopic disorders with gamma-interferon
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
WO1997007820A1 (fr) * 1995-08-30 1997-03-06 Toray Industries, Inc. Remede destine aux maladies cardiaques
NZ506854A (en) * 1998-04-02 2003-07-25 Genentech Inc Treatment of cardiac hypertrophy

Also Published As

Publication number Publication date
EP1067958A2 (de) 2001-01-17
DK1067958T3 (da) 2006-11-06
HK1099197A1 (en) 2007-08-10
IL138812A0 (en) 2001-10-31
ES2314786T3 (es) 2009-03-16
JP2002510645A (ja) 2002-04-09
DE69932235D1 (de) 2006-08-17
JP2009256375A (ja) 2009-11-05
CA2325442C (en) 2011-10-11
DE69932235T2 (de) 2007-06-14
BR9909422A (pt) 2001-09-11
DK1702623T3 (da) 2009-01-19
CN1201814C (zh) 2005-05-18
WO1999051260A3 (en) 1999-12-09
EP1702623A2 (de) 2006-09-20
EP1067958B1 (de) 2006-07-05
US6187304B1 (en) 2001-02-13
NZ506854A (en) 2003-07-25
TWI243682B (en) 2005-11-21
EP1702623B1 (de) 2008-10-08
AU757910B2 (en) 2003-03-13
CN1300221A (zh) 2001-06-20
EP1702623A3 (de) 2007-01-10
JP5030329B2 (ja) 2012-09-19
DE69939723D1 (de) 2008-11-20
ATE410181T1 (de) 2008-10-15
HK1036019A1 (en) 2001-12-21
ZA200004854B (en) 2001-09-26
ES2267258T3 (es) 2007-03-01
AU3102499A (en) 1999-10-25
US6989364B1 (en) 2006-01-24
AR018174A1 (es) 2001-10-31
CA2325442A1 (en) 1999-10-14
WO1999051260A2 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ATE300597T1 (de) Behandlung von geweben
ATE260332T1 (de) Behandlung von textilien
DE69831134D1 (de) Behandlung von wasser
DE69835011D1 (de) Unterschiedliche behandlung von prothesenteilen
DE69817446D1 (de) Behandlung von diabetes
DE69500089D1 (de) Behandlung von Geflügel
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DE69716647D1 (de) Biologische behandlung von gebrauchten kaustischen laugen
ATE298241T1 (de) Behandlung von atemstillstand im schlaf
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
ATE349216T1 (de) Behandlung von darmverstopfung
DE60001421D1 (de) Behandlung von abgas
EP0996433A4 (de) Behandlungsverfahren von lactosylceramidbedingten zuständen
DE69922631D1 (de) Superkritische behandlung von aktivkohle
EP1117431A4 (de) Behandlung von acidose
ATE332144T1 (de) Behandlung von herzhypertrophie
DE69810499D1 (de) Behandlung von industriegeweben
EP1239851A4 (de) Behandlung von hyperproliferativen erkrankungen
DE60026821D1 (de) Behandlung von bohrspülung
DE60103685D1 (de) Behandlung von Poriomania
DE69904762T2 (de) Behandlung von flachs-saatgut
ATE235494T1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1067958

Country of ref document: EP